Horizon Pharma Begins Hostile Bid for Depomed After Rebuffs

Updated on

Horizon Pharma Plc took its $1.68 billion takeover offer directly to shareholders of Depomed Inc. after the California drugmaker’s board spurned previous approaches.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.